GBA PRESENTS- the public games

Discussion in 'Stocks' started by stonedinvestor, Jul 22, 2024.


  1. +16.06%

    WAKIX (pitolisant) Net Revenue of$186.0 Millionfor Third Quarter 2024; Surpassed$2Bin Cumulative Net Revenue in Less Than Five Years

    On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study

    Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Potential Best-In-Class, Novel Orexin-2 Agonist On Track for mid-2025, Extending Leadership in Sleep/Wake Beyond 2040s
     
    #4551     Oct 30, 2024


  2. Well what point could be made by highlighting Schoals at $17 with a date of 04'

    And yes I knew all along that was military time or something.. but why did they write 04:00

    That was weird.

    I am presenting a bottom case a year later.
     
    #4552     Oct 30, 2024
  3. Tricky HRMY slipped this in yest with earn:

    Harmony Biosciences announces 8M share offering of common stock for holders » 17:17 HRMY
     
    #4553     Oct 30, 2024
  4. vanzandt

    vanzandt

    '04?
    Whaaaaaat are you talking about?
     
    #4554     Oct 30, 2024
  5. I always wondered: who the Fuck is EF Hutton?


    Quince Therapeutics (NASDAQ:QNCX) Raised to Strong-Buy at EF Hutton Acquisition Co. I
    Oct 25th, 2024



    EF Hutton analyst Jason Kolbert initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $12 price target Quince is a biotechnology company focused on developing precision therapeutics for rare diseases, the analyst tells investors in a research note. The firm says the company stands out in the biotechnology space, focusing on developing precision therapeutics initially aimed at rare and ultra-orphan diseases, particularly ataxia-telangiectasia. Quince is positioned to make a “meaningful impact in the rare disease space, enhancing patient outcomes and shareholder value,” contends EF.

    Ok so the rare disease part I do not like. The upside you will have every disease to yourself no competition and the FDA is likely to be on your side.

    The down side no huge market to extrapolate sales.

    Still it is hard to ignore this is two upgrades in a week with $10- $11 PT's on a $1 name.. and you just don't see that often...
     
    #4555     Oct 30, 2024


  6. Go look at the timestamp for the post you made on Schoels it says Oct 10th or 15th 04.<--

    It was very confusing because Schoals has been very cheap all year. It should of said 03'
     
    #4556     Oct 30, 2024
  7. WE HAVE HAD A SURGE!

    Views:
    90,282
     
    #4557     Oct 30, 2024
    vanzandt likes this.
  8. vanzandt

    vanzandt

    Stoney, I hit "reply" on those. I altered NOTHING. Look at them for christ sake. I post screenshots 3X. Post a screenshot of that which you are talking about. Either way, I didn't change a f'ing thing bro. For real.
     
    #4558     Oct 30, 2024
  9. vanzandt

    vanzandt

    Here, I'll help. This is a screenshot of the post in question, minus my red text. Where is anything altered from your original posts?

    upload_2024-10-30_8-14-10.jpeg
     
    #4559     Oct 30, 2024
  10. vanzandt

    vanzandt

    I even wrote if you look... "It was a year ago when you post that".... referring to the quote above it. :rolleyes:
     
    #4560     Oct 30, 2024